Cytokinetics Announces Positive Results from ACACIA-HCM Presented in Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 and Published in The New England ...

ACACIA-HCM is the First Phase 3 Clinical Trial to Successfully Demonstrate Statistically Significant Improvements Across Both Patient-Reported and Physician-Assessed Endpoints in Non-Obstructive HCM ...

Cytokinetics’ Aficamten Hits Dual Phase III Endpoints in Non-Obstructive HCM

Cytokinetics (NASDAQ:CYTK) presented primary results from its Phase III ACACIA-HCM trial evaluating aficamten in patients ...

AI Isn’t Killing Marketing Accountability, It’s Exposing Who Never Had It

A bookstore's AI-altered ad exposed a gap most marketing teams haven't fixed – nobody owns what AI changes after approval.